InflaRx (IFRX) Stock Forecast & Price Target

InflaRx NV's product candidate, vilobelimab, has shown promising results in improving survival rates, with a relative reduction in 28-day all-cause mortality of 23.9%, indicating its potential significance in treating autoimmune and inflammatory diseases. The therapy demonstrated a well-tolerated profile, contributing to reduced corticosteroid use and enabling corticosteroid-free treatment options for patients, which could enhance patient outcomes and satisfaction. Additionally, significant placebo-adjusted reductions in disease metrics—specifically 45.2% for dT, 25.1% for ANdT, and 31.6% for IHS4—underline the efficacy of vilobelimab as it enters further stages of clinical development.

InflaRx NV faces a negative outlook due to depressed forward multiples, which are attributed to increased market volatility impacting investor sentiment. Additionally, the company's high cash burn rate raises concerns, particularly as it relies on the success of its development programs and uncertain partner revenue to mitigate these costs. Furthermore, the stagnant projected revenue from its product GOHIBIC indicates the asset is not poised for growth, contributing to the cautious financial outlook for the company.